Results 21 to 30 of about 3,744 (163)
Right heart thrombi (RHT) and clot in transit with concomitant PE management: Approach and considerations
Pulmonary Circulation, Volume 12, Issue 2, April 2022., 2022 Abstract
Right heart thrombi (RHT) continues to pose a clinical dilemma for multiple specialties and is especially concerning when present with concomitant pulmonary embolism (PE). Patients with PE and RHT are at an increased risk of poor outcomes compared to PE without RHT. Although the exact incidence of RHT is unknown, the increasing use of point‐of‐Akhil Khosla, Hamid Mojibian, Roland Assi, Hossam Tantawy, Inderjit Singh, Jeffrey Pollak +5 morewiley +1 more sourceInternational pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis
Journal of Thrombosis and Haemostasis, Volume 19, Issue 4, Page 1123-1129, April 2021., 2021 Abstract
Pediatric thromboembolism is a rare and heterogenous disease. As a result, there is a paucity of knowledge with regard to natural history, management, and outcomes of most types of pediatric venous and arterial thromboembolism. International research collaboration is needed to fill these knowledge gaps.C. Heleen van Ommen, Manuela Albisetti, Mohir Bhatt, Marianne Bonduel, Brian Branchford, Elizabeth Chalmers, Anthony Chan, Neil A. Goldenberg, Susanne Holzhauer, Paul Monagle, Ulrike Nowak‐Göttl, Shoshana Revel‐Vilk, Gabriela Sciuccatie, Nongnuch Sirachainan, Christoph Male, for the Subcommittee on Pediatric, Neonatal Thrombosis, Hemostasis +17 morewiley +1 more sourceAnticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
Research and Practice in Thrombosis and Haemostasis, Volume 5, Issue 3, Page 426-438, March 2021., 2021 Abstract Background
The XALIA and XALIA‐LEA prospective, noninterventional studies investigated the safety and effectiveness of rivaroxaban versus standard anticoagulation for venous thromboembolism (VTE) treatment in routine clinical practice across global regions.Sylvia Haas, Lorenzo G. Mantovani, Reinhold Kreutz, Danja Monje, Jonas Schneider, Elizabeth R. Zell, Miriam Tamm, Martin Gebel, Jörg‐Peter Bugge, Walter Ageno, Alexander G. G. Turpie +10 morewiley +1 more sourceProvoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
Research and Practice in Thrombosis and Haemostasis, Volume 5, Issue 2, Page 326-341, February 2021., 2021 Abstract Introduction
Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent on the presence or absence of provoking risk factors at the time of the event. Objective
To compare clinical characteristics, anticoagulant patterns, and 12‐month outcomes in patients with transient provoking factors, active cancer, and unprovoked VTE ...Walter Ageno, Alfredo Farjat, Sylvia Haas, Jeffrey I. Weitz, Samuel Z. Goldhaber, Alexander G. G. Turpie, Shinya Goto, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Gloria Kayani, Sebastian Schellong, Henri Bounameaux, Lorenzo G. Mantovani, Paolo Prandoni, Ajay K. Kakkar +14 morewiley +1 more sourceSymptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
Research and Practice in Thrombosis and Haemostasis, Volume 5, Issue 1, Page 168-178, January 2021., 2021 Abstract Background
The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. Methods
We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs.Carmen Fernández‐Capitán, Ana Rodriguez Cobo, David Jiménez, Olga Madridano, Maurizio Ciammaichella, Esther Usandizaga, Remedios Otero, Pierpaolo Di Micco, Farès Moustafa, Manuel Monreal, The RIETE Investigators, M. D. Adarraga, M. A. Aibar, M. Alfonsa, J. I. Arcelus, P. Azcarate‐Agüero, A. Ballaz, P. Baños, R. Barba, M. Barrón, B. Barrón‐Andrés, J. Bascuñana, A. Blanco‐Molina, A. M. Camón, L. Chasco, A. J Cruz, R. del Pozo, J. de Miguel, J. del Toro, M. C. Díaz‐Pedroche, J. A. Díaz‐Peromingo, J. C. Escribano, C. Falgá, C. Fernández‐Aracil, M. A. Fidalgo, C. Font, L. Font, M. A. García, F. García‐Bragado, M. García‐Morillo, A. García‐Raso, A. I. García‐Sánchez, O. Gavín, I. Gaya, C. Gómez, V. Gómez, J. González, E. Grau, R. Guijarro, J. Gutiérrez, G. Hernández‐Comes, L. Hernández‐Blasco, E. Hernando, L. Jara‐Palomares, M. J. Jaras, D. Jiménez, M. D. Joya, J. Lima, P. Llamas, J. L. Lobo, R. López‐Reyes, J. B. López‐Sáez, M. A. Lorente, A. Lorenzo, M. Lumbierres, A. Maestre, P. J. Marchena, F. Martín‐Martos, M. Martín‐Romero, M. V Morales, J. A. Nieto, S. Nieto, A. Núñez, M. J. Núñez, M. Odriozola, M. C. Olivares, S. Otalora, J. M. Pedrajas, G. Pellejero, C. Pérez‐Ductor, M. L Peris, I. Pons, J. A. Porras, L. Ramírez, O. Reig, A. Riera‐Mestre, D. Riesco, A. Rivas, M. A. Rodríguez‐Dávila, V. Rosa, P. Ruiz‐Artacho, J. C. Sahuquillo, M. C. Sala‐Sainz, A. Sampériz, R. Sánchez‐Martínez, S. Soler, B. Sopeña, J. M Suriñach, C. Tolosa, M. I Torres, J. Troya, J. Trujillo‐Santos, F. Uresandi, B. Valero, R. Valle, J. Vela, L. Vela, G. Vidal, A. Villalobos, T. Vanassche, C. Vandenbriele, P. Verhamme, H. H. B. Yoo, P. Wells, J. Hirmerova, R. Malý, E. Salgado, L. Bertoletti, A. Bura‐Riviere, N. Falvo, D. Farge‐Bancel, A. Hij, I. Mahé, I. Quere, A. Braester, B. Brenner, M. Ellis, I. Tzoran, G. Antonucci, G. Barillari, F. Bilora, C. Bortoluzzi, E. Bucherini, A. Camerota, C. Cattabiani, F. Dentali, R. Duce, M. Giorgi‐Pierfranceschi, E. Grandone, E. Imbalzano, G. Lessiani, R. Maida, D. Mastroiacovo, F. Pace, R. Pesavento, M. Pesavento, R. Poggio, P. Prandoni, R. Quintavalla, A. Rocci, C. Siniscalchi, E. Tiraferri, D. Tonello, A. Visonà, B. Zalunardo, V. Gibietis, A. Skride, B. Vitola, A. Alatri, H. Bounameaux, L. Calanca, L. Mazzolai +161 morewiley +1 more sourceEdoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
Clinical and Translational Science, Volume 14, Issue 1, Page 335-342, January 2021., 2021 Edoxaban is used for venous thromboembolism (VTE) treatment. Real‐life data are lacking about its use in long‐term therapy. We aimed to assess the efficacy and the safety of edoxaban for long‐term VTE treatment in a real‐life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban Giuseppe Camporese, Paolo Simioni, Pierpaolo Di Micco, Carmen Fernández‐Capitán, Agustina Rivas, Carme Font, Joan Carles Sahuquillo, Paula Villares, Paolo Prandoni, Manuel Monreal, and the RIETE Investigators +10 morewiley +1 more sourceGenotipos frecuentemente asociados a trombofilias
Biomédica: revista del Instituto Nacional de Salud, 2014 La enfermedad tromboembólica venosa es una entidad patológica importante debido a la morbilidad que causa, por sus complicaciones y por su alta incidencia en el mundo, la cual puede variar desde 1:100 en adultos mayores hasta 1:100.000 en niños.Helena Hernández-Cuervo, Solangy Usme, Juan José Yunis +2 moredoaj +1 more source